risedronate sodium 35mg tablets
a a h pharmaceuticals ltd - risedronate sodium - oral tablet - 35mg
risedronate sodium 35mg tablets
de pharmaceuticals - risedronate sodium - oral tablet - 35mg
risedronate sodium 35mg tablets
viatris uk healthcare ltd - risedronate sodium - oral tablet - 35mg
risedronate sodium tablet, delayed release
zydus lifesciences limited - risedronate sodium anhydrous (unii: ofg5exg60l) (risedronic acid - unii:km2z91756z) - risedronate sodium delayed-release tablets are indicated for the treatment of osteoporosis in postmenopausal women. in postmenopausal women, risedronate sodium has been shown to reduce the incidence of vertebral fractures and a composite endpoint of nonvertebral osteoporosis-related fractures [see clinical studies (14.1) ]. the optimal duration of use has not been determined. the safety and effectiveness of risedronate sodium delayed-release tablets for the treatment of osteoporosis are based on clinical data of one year duration. all patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. patients at low-risk for fracture should be considered for drug discontinuation after 3 to 5 years of use. patients who discontinue therapy should have their risk for fracture re-evaluated periodically. risedronate sodium delayed-release tablets are contraindicated in patients with the following conditions: - abnormalities of the esophagus which delay esophageal e
risedronate sodium tablet, delayed release
sun pharmaceutical industires inc. - risedronate sodium (unii: ofg5exg60l) (risedronic acid - unii:km2z91756z) - risedronate sodium delayed-release tablets are indicated for the treatment of osteoporosis in postmenopausal women. in postmenopausal women, risedronate sodium has been shown to reduce the incidence of vertebral fractures and a composite endpoint of nonvertebral osteoporosis-related fractures [see clinical studies (14.1) ]. the optimal duration of use has not been determined. the safety and effectiveness of risedronate sodium delayed-release tablets for the treatment of osteoporosis are based on clinical data of one year duration. all patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. patients at low-risk for fracture should be considered for drug discontinuation after 3 to 5 years of use. patients who discontinue therapy should have their risk for fracture re-evaluated periodically. risk summary available data on use of risedronate sodium in pregnant women are insufficient to inform drug-associated risk of adverse maternal or fetal outcomes. discon
risedronate sodium tablet, delayed release
northstar rxllc - risedronate sodium (unii: ofg5exg60l) (risedronic acid - unii:km2z91756z) - risedronate sodium delayed-release tablets are indicated for the treatment of osteoporosis in postmenopausal women. in postmenopausal women, risedronate sodium has been shown to reduce the incidence of vertebral fractures and a composite endpoint of nonvertebral osteoporosis-related fractures [see clinical studies (14.1) ]. the optimal duration of use has not been determined. the safety and effectiveness of risedronate sodium delayed-release tablets for the treatment of osteoporosis are based on clinical data of one year duration. all patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. patients at low-risk for fracture should be considered for drug discontinuation after 3 to 5 years of use. patients who discontinue therapy should have their risk for fracture re-evaluated periodically. risk summary available data on use of risedronate sodium in pregnant women are insufficient to inform drug-associated risk of adverse maternal or fetal outcomes. discon
risedronate mylan once a week 35mg film-coated tablets
mcdermott laboratories ltd t/a gerard laboratories - risedronate sodium hemipentahydrate - film-coated tablet - 35 milligram(s) - bisphosphonates; risedronic acid
risedronate sodium accord once a week 35 mg film-coated tablets
pco manufacturing ltd. - risedronate sodium - film-coated tablet - 35 milligram(s) - risedronic acid
risedronate 30mg film-coated tablets 30 milligram film coated tablet
aspire pharma limited - risedronate sodium - film coated tablet - 30 milligram
risedronate 5mg film-coated tablets 5 milligram film coated tablet
aspire pharma limited - risedronate sodium - film coated tablet - 5 milligram